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Abstract: Olanzapine is an atypical antipsychotic currently with indications for the treatment 
of schizophrenia, acute mania and the prevention of relapse in bipolar disorder. A growing 
body of clinical evidence supports these indications. Acute mania trials have demonstrated 
superior efﬁ  cacy of olanzapine to placebo, equal or superior efﬁ  cacy to valproate and superior 
efﬁ  cacy in combination therapy with lithium or valproate compared to mood stabilizer mono-
therapy. Olanzapine demonstrated a modest effect in the treatment of bipolar depression with 
a substantially enhanced effect in combination with ﬂ  uoxetine. Maintenance trials showed 
olanzapine to be more efﬁ  cacious than placebo in the prevention of manic and depressive 
relapses and non-inferior to lithium or valproate. Combination of olanzapine with lithium or 
valproate was also found to be more efﬁ  cacious than lithium or valproate monotherapy in the 
prevention of manic relapse in patients with a partial response to monotherapy with lithium or 
valproate. These trials suggest that olanzapine is a viable option and an invaluable addition to 
the pharmacological armamentarium in the treatment of bipolar I disorder. However, this can 
often be mitigated by safety and tolerability concerns with this agent including weight gain 
and metabolic syndrome that warrants clinician vigilance and discernment that is imperative 
in today’s clinical practice.
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Introduction
Bipolar disorder is a common psychiatric illness with a highly variable course and 
high rates of morbidity and mortality requiring lifelong treatment. It has an estimated 
prevalence of 1.6%–3.7%, and is an episodic illness interspersed with erratic cycles 
of mania and depression or mixed episodes (Kessler et al 1997; Hirschﬁ  eld et al 
2003). The complex nature of this malady poses several diagnostic and therapeutic 
challenges. Bipolar disorder carries a high socioeconomic burden given the rates of 
suicide (15%), the phasic symptoms resulting in relapses, recurrences, rehospitaliza-
tion, and decreased productivity resulting in poor quality of life for the consumer. 
Clinical treatment guidelines provide broad recommendations to help clinicians select 
appropriate treatment alternatives based on the polarity of an episode, mixed state or 
psychotic symptoms, number of episodes, prior response to treatment and/or presence 
of comorbidities.
Substantial advances in the recent years have fostered an expansion in the phar-
macological treatment options for bipolar disorder, but optimal management of this 
devastating illness continues to remain an elusive goal. Best clinical evidence with 
mood stabilizers including lithium, valproate, lamotrigine, and carbamazepine, as 
well as the atypical antipsychotics olanzapine, risperidone, quetiapine, ziprasidone, 
and aripiprazole suggests that these agents are more effective for symptoms of mood 
elevation than for symptoms of depression. Clinical Treatment Guidelines, Expert 
Consensus and Texas Medication Algorithm Project recommend antipsychotic and Neuropsychiatric Disease and Treatment 2007:3(5) 580
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mood stabilizer monotherapy as well as combination with 
traditional mood stabilizing medications (APA 2002; Keck 
et al 2004; Suppes et al 2005). First generation antipsy-
chotics have a role in combination with traditional mood 
stabilizers for acute mania but appear to worsen depressive 
symptoms. Their utility is also limited by their side-effect 
proﬁ  le, especially extrapyramidal symptoms, tardive dys-
kinesia and sexual dysfunction. With the introduction of 
second generation antipsychotic medications, there has been 
a renewed interest in the utility of this class of medications 
in managing acute mania, depression, mixed states and 
maintenance treatment. Our ﬁ  eld over the last decade or 
so has seen a tremendous wealth of data documenting the 
use of atypical antipsychotics in bipolar mania, depression, 
mixed states and relapse prevention. So far all antipsychotic 
agents with the exception of clozapine have been approved 
for the treatment of acute mania. The beneﬁ  cial effects of 
atypical antipsychotics are often mitigated by an increased 
risk of metabolic abnormalities such as dyslipidemia, 
hyperglycemia, and diabetes mellitus in a population that 
is already at a heightened risk for metabolic syndrome and 
cardiovascular morbidity and mortality. Several agents used 
in acute and prophylactic mania treatment including lithium, 
valproate, olanzapine, quetiapine, and risperidone can cause 
problematic weight gain, which often can set the stage for 
non-adherence. Treatment non-adherence is a major concern 
in bipolar disorder with nearly half of individuals being non-
adherent to psychotropic medication they are prescribed. 
Prudent practice demands a good risk beneﬁ  t analysis in 
choosing an agent that is efﬁ  cacious, safe and well tolerated 
when making clinical decisions.
Olanzapine was the ﬁ  rst atypical antipsychotic to receive 
an indication for acute mania. Olanzapine is currently 
approved not only for the treatment of schizophrenia, but 
also for the treatment of acute mania and maintenance and 
relapse prevention of mania in patients successfully treated 
with this drug. It is now the most studied medication in 
randomized clinical controlled trials in bipolar disorder, 
surpassing lithium in its body of evidence. This paper will 
critically review available randomized clinical trials utilizing 
olanzapine in bipolar disorder.
Pharmacology
Olanzapine is a second-generation antipsychotic agent 
that exhibits a wide array of receptor afﬁ  nities including 
5-HT2A–C,3,6,7, dopaminergic D1–5, muscarinic M1–5, α1- 
adrenergic and histaminergic H1 receptors (Bymaster et al 
1997). These receptor afﬁ  nities have been shown to relate to 
recognized clinical and adverse effects of olanzapine. The 
primary antimanic and antipsychotic effects are likely regu-
lated by the blockade of dopamine D2 and serotonin 5-HT2A 
receptors primarily in the mesolimbic pathway. Olanzapine 
is relatively nonselective at dopamine receptor subtypes, and 
it shows selectivity for mesolimbic and mesocortical over 
striatal dopamine tracts (Casey 1997). Olanzapine exhibits 
linear pharmacokinetic properties across the clinical dos-
age range of 0.5 to 20 mg (Callaghan et al 1999). It is well 
absorbed orally with peak concentrations occurring 4–6 hours 
after oral administration (Kassahun et al 1997).
Hepatic metabolism and drug-drug 
interactions
Olanzapine is metabolized rapidly by the cytochrome P450 
(CYP) 1A2 system, which accounts for approximately 
50%–60% of its metabolism (deLeon et al 2005). The 
remainder of metabolism occurs through the CYP2D6 
system, the ﬂ  avin mono-oxygenase-3 system, and uridine 
5'-diphosphate glucuronosyltransferases (UGTs), possibly 
UGT1A4 (deLeon et al 2005). Because of its metabolism, 
the clearance is moderately reduced by CYP1A2 inhibitors 
such as ﬂ  uvoxamine and CYP2D6 inhibitors such as ﬂ  uox-
etine, paroxetine and bupropion, and increased by CYP1A2 
inducers such as carbamazepine (deLeon et al 2005). Poly-
cyclic aromatic hydrocarbons in tobacco smoke can induce 
metabolism, and smoking cessation can thus be expected to 
increase an average patient’s drug level by an average of 1.5 
fold two to four weeks later (deLeon et al 2005). Olanzapine 
is excreted primarily in the urine with a mean half-life of 36 
hours (Casey 1997).
Efﬁ  cacy studies
Olanzapine has been shown to be efﬁ  cacious and is also 
FDA indicated for both acute and maintenance treatment of 
bipolar I disorder. These indications are based on a number 
of clinical trials summarized in Tables 1 and 2.
Acute manic or mixed episodes
Our search resulted in six double-blind studies that evaluated 
the efﬁ  cacy of olanzapine compared to placebo, divalproex 
and haloperidol in acute mania or mixed episodes. In each 
of these studies, olanzapine was found to be efﬁ  cacious 
in the reduction of symptoms related to mania or mixed 
episodes.
The ﬁ  rst of the placebo-controlled trials (Tohen et al 
1999) was a three week trial which demonstrated a mean 
change in Young Mania Rating Scale (YMRS) of –10.26 in Neuropsychiatric Disease and Treatment 2007:3(5) 581
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the olanzapine group and –4.88 in the placebo group, with 
48.6% of patients being responders in the olanzapine-treated 
group compared to 24.2% of the placebo-treated group. 
Olanzapine at a mean modal dose of 14.9 mg was shown to 
be superior to placebo in the treatment of acute symptoms 
of mania in this trial. The limitations to this study were the 
high drop out rate in the placebo group, and allowance of 
concomitant use of lorazepam up to 4 mg daily for the ﬁ  rst 
seven days then 2 mg daily for an additional 3 days, which 
in total constituted almost half of the study length.
In the other double-blind, placebo-controlled trial (Tohen 
et al 2000) the mean change in YMRS over four weeks in 
the olanzapine group and placebo group were –14.8 and –8.1 
respectively. Sixty-ﬁ  ve percent of patients in the olanzapine-
treated group were responders compared to forty-three 
percent in the placebo-treated group. Olanzapine at a mean 
modal dose of 16.4 mg was shown to be superior to placebo 
in the treatment of acute symptoms of mania in this trial. 
This study was one week longer than the previous placebo-
controlled trial and allowed lower doses of concomitant 
Table 1 Olanzapine in the treatment of acute manic or mixed episodes in bipolar I disorder
Reference  Treatment   Duration   Mean dose   YMRS   Percent 
 arms  (weeks)  (mg/day)  change  responders
Tohen et al 1999  Olanzapine  3  14.9  –10.26  48.6%
 Placebo  3    –4.88  24.2%
Tohen et al 2000  Olanzapine  4  16.4  –14.8  65%
 Placebo  4    –8.1  43%
Tohen et al 2002   Olanzapine  3  17.4  –13.4  54.4%
 Divalproex  3  1401.2  –10.4  42.3%
Zajecka et al 2002  Olanzapine  12  14.7  –17.2a Not  reported
 Divalproex  12  2115  –14.8a Not  reported
Berk et al 1999  Olanzapine  4  10  –21.5a Not  reported
 Lithium  4  800  –18.4a Not  reported
Tohen et al 2003  Olanzapine  6  15.0a   –21.3b 72.3%b
     12  11.4b –26.5c 96.3%c
 Haloperidol  6  7.1a –23.5b 74.2%b
   12  5.2b –26.8c 94.1%c
anot a statistically signiﬁ  cant difference between groups in the study; these studies also used a mania rating scale that was not the YMRS.
bvalue from week 6 data.
cvalue from week 12 data.
Abbreviation: YMRS, young mania rating scale.
Response deﬁ  ned as 50% or more improvement in YMRS.
Table 2 Olanzapine in the maintenance treatment of bipolar I disorder
Reference  Treatment  Duration  Mean dose  Median time  Relapse
   arms  (weeks)  (mg/day)  to  relapse  (days)  rate
Tohen et al 2003  Olanzapine  47  16.2  27a 42.4%
         
   Divalproex  47  1584.7  27a 56.5%
Tohen et al 2004  Olanzapine +   78  OLZ = 8.6  163  37%b
    (Li or DV)     Li = 1064.6   
        DV = 1264.6   
    Li or DV   78  Li = 1023.8  42  55%b
    Monotherapy    DV = 1286.5   
Tohen et al 2005  Olanzapine  52  11.9  Not reported  30.0%
        
   Lithium  52  1102.7  Not  reported  38.8%
Tohen et al 2006  Olanzapine  48  12.5  174  46.7%
        
   Placebo  48    22  80.1%
Relapse deﬁ  ned as symptomatic recurrence of any affective episode.
a25th percentile reported instead of median time.
bnot a statistically signiﬁ  cant difference between groups in the study.
Abbreviations: Li,  lithium; DV,  divalproex sodium.Neuropsychiatric Disease and Treatment 2007:3(5) 582
Narasimhan et al
lorazepam (up to 2 mg daily for ﬁ  rst four days then up to 
1 mg daily for the next six days). Neither study utilized an 
active comparator treatment arm.
Two studies (Tohen, Baker et al 2002; Zajecka et al 
2002) compared olanzapine to divalproex in the treatment 
of acute mania or mixed mania. Olanzapine was found to be 
efﬁ  cacious in both studies. However, in the study by Tohen, 
Baker et al (2002), it was determined to be signiﬁ  cantly bet-
ter than divalproex in reduction of manic symptoms, while 
in the study performed by Zajecka and colleagues (2002), 
there was no signiﬁ  cant differences between the two groups. 
The main difference between the two studies was in dosing 
(non-loading versus loading) of the two agents, with the 
study that showed superiority of olanzapine (Tohen, Baker 
et al 2002) having initial dosing of olanzapine very similar 
to the mean modal dose for the study (15 mg/day versus 
17.4 mg/day) while initial dosing of divalproex was much 
lower than the mean modal dose for the study (750 mg/day 
versus 1401.2 mg/day), suggesting the olanzapine was more 
effectively dosed from the onset. The study (Zajecka et al 
2002) that showed no difference between olanzapine and 
divalproex also had fewer subjects overall (120 compared 
to 248), used the Mania Rating Scale instead of the YMRS, 
and did not report percentage of responders. Since dival-
proex is considered a ﬁ  rst-line treatment for mania, even an 
equivalent response is sufﬁ  cient to demonstrate efﬁ  cacy of 
olanzapine in mania.
As lithium is still considered the gold standard for bipolar 
treatment, it is signiﬁ  cant to note that a head-to-head trial 
(Berk et al 1999) comparing ﬁ  fteen patients given 10 mg 
total daily olanzapine to ﬁ  fteen patients given 800 mg daily 
lithium over a four-week period produced no signiﬁ  cant 
differences in Mania Scale, brief psychiatric rating scale 
(BPRS), or clinical global impression (CGI) improvement 
scores. Olanzapine did have a statistically signiﬁ  cant supe-
riority to lithium in the CGI severity scale at week 4 in this 
study. The study does provide some evidence to the assertion 
that olanzapine is effective in the treatment of mania based 
on the CGI difference. Given the limitation of a small sample 
size, larger trials comparing these agents to demonstrate 
comparative efﬁ  cacy would be useful to elucidate and sup-
port these ﬁ  ndings. Also, since a placebo arm was not used 
in this trial, an assertion of no difference could show merely 
that the statistical power was not sufﬁ  cient to separate an 
effective from an ineffective treatment.
In a study (Tohen, Baker, et al 2003) comparing olanzap-
ine to haloperidol, additional information about the efﬁ  cacy 
of olanzapine in mania is reported. The results showed an 
increased response rate of  50% improvement in YMRS 
at 12 weeks compared to 6 weeks for both olanzapine-
treated subjects and haloperidol-treated subjects. There were 
statistically signiﬁ  cant differences between the groups with 
haloperidol faring better in the reduction of manic symp-
toms by the end of six weeks and olanzapine faring better 
in the reduction of manic symptoms from week six to week 
12, although the groups were statistically similar by week 
12. The estimated median time to ﬁ  rst remission (deﬁ  ned 
by a YMRS score of 12 or lower and a HAMD-21 score 
of 8 or lower) was 34 days for this group. There were no 
signiﬁ  cant differences in response or remission between the 
haloperidol and olanzapine groups, except that olanzapine 
was found to be signiﬁ  cantly more effective than haloperidol 
in patients without psychotic features (56.7% versus 41.6%). 
The authors suggested the ﬁ  ndings might indicate that the 
anti-manic efﬁ  cacy of olanzapine is independent of its anti-
psychotic properties.
In a 6-week double-blind, randomized trial by Tohen, 
Chengappa et al (2002) designed to evaluate the efﬁ  cacy of 
olanzapine compared to placebo as an augmenting agent for 
patients with acute manic or mixed bipolar episodes with 
an inadequate response to at least two weeks of lithium or 
valproate therapy showed the addition of olanzapine provided 
superior efﬁ  cacy to continued monotherapy with lithium or 
valproate in these patients that were poorly responsive to 
monotherapy after at least two weeks. Olanzapine augmenta-
tion produced superior YMRS improvements (–13.11 versus 
–9.1 change from baseline; p = 0.003) and clinical response 
rates (67.7% versus 44.7%; p   0.001).
A unique study (Baker et al 2003) that has bearing on use 
of olanzapine in acute mania studied the effectiveness of rapid 
initial dose escalation (RIDE) of oral olanzapine versus usual 
clinical practice in patients with acute agitation. The RIDE 
method involves use of up to 40 mg olanzapine on days one and 
two, up to 30 mg on days three and four and 5 mg/d to 20 mg/d 
after day four. The usual clinical practice method involves use 
of 10 mg/d olanzapine plus up to 4 mg lorazepam on days one 
and two and up to 2 mg lorazepam on days three and four then 
olanzapine 5 mg/day to 20 mg/day after day four. Although 
this study enrolled patients with psychosis-related diagnoses 
(71.6% of those enrolled) and bipolar I disorder (28.4%), the 
results revealed the RIDE group had signiﬁ  cant improvements 
over the usual clinical practice group in controlling acute 
agitation. These results may be useful in acute mania, though 
it would be best to have a similar study involving only those 
patients diagnosed with Bipolar I disorder. The study discus-
sion also questioned whether a higher dosing than the usual Neuropsychiatric Disease and Treatment 2007:3(5) 583
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20 mg/day of oral olanzapine prominent in the acute mania 
trials could provide better mania outcomes.
Maintenance therapy
There are four randomized, double-blind trials investigating 
the efﬁ  cacy of olanzapine compared to placebo, lithium or 
divalproex monotherapy as well as augmentation in mainte-
nance therapy or prevention of relapse of affective episodes 
in bipolar I disorder. The studies varied in length from 47 to 
78 weeks with the dosing and efﬁ  cacy results summarized 
in Table 2. These studies help support the use of olanzapine 
in relapse prevention in bipolar disorder due to the favorable 
results in efﬁ  cacy in the olanzapine-treated patients.
Tohen, Ketter et al (2003) compared the efﬁ  cacy of 
olanzapine to divalproex, evaluating a total of 251 patients 
with manic or mixed episodes. Patients with YMRS scores 
of  20 were included. Symptomatic remission was deﬁ  ned 
as a YMRS  12 while symptomatic relapse was deﬁ  ned as 
a YMRS  15 for a manic episode or a Hamilton depression 
rating scale  15 for a depressive episode. The study partici-
pants initially entered a 3-week study comparing efﬁ  cacy for 
acute mania, with responders entering a 44-week double-blind 
extension period. The 25th percentile of time to relapse was 
reported in both the olanzapine and divalproex groups as 27 
days (Table 2) rather than reporting a median time to relapse. 
The authors reported that rates of remission were greater in 
both groups at endpoint than at week 3. Rates of relapse did 
not differ signiﬁ  cantly between the two groups. Because the 
study was not speciﬁ  cally designed to address relapse preven-
tion, the authors noted limitations in its design. Patients were 
not in remission at the start of the study, but rather were in 
an acute manic or mixed episode. Also, the study had a high 
dropout rate with ﬁ  nal relapse rates based on 33 olanzapine-
treated patients and 23 divalproex-treated patients.
Tohen and colleagues (2004) compared combination of 
olanzapine and a mood stabilizer (lithium or divalproex) 
to mood stabilizer monotherapy. The combination-treated 
group showed a statistically signiﬁ  cant increase (163 days 
versus 42 days; p = 0.023) in time to symptomatic relapse, 
but did not statistically separate from monotherapy in rate 
of relapse (37% versus 55%; p = 0.149). There was also no 
signiﬁ  cant difference between groups in time to syndromic 
relapse (94 days versus 40.5 days; p = 0.742). One limita-
tion of particular interest is that the patients in the study in 
the authors’ own words, represent an “enriched” sample, 
because they were required to show incomplete responses 
to monotherapy and then respond satisfactorily to combina-
tion therapy with olanzapine. Also, the mean blood levels 
of valproate were on the lower end of the therapeutic range 
at 67.8 μg/mL in combination therapy and 66.3 μg/mL in 
monotherapy.
In a study comparing olanzapine to lithium for bipolar 
relapse prevention for 12 months, Tohen and colleagues 
(2005) found olanzapine to be statistically non-inferior to 
lithium. This study enrolled patients with YMRS scores  20. 
The subjects were initially treated with a combination of 
olanzapine and lithium. Those patients who met symptomatic 
remission criteria after 6–12 weeks in an open label phase 
were randomized to monotherapy with lithium or olanzap-
ine. During the next four weeks, the additional medication 
from the open label phase was tapered and discontinued. 
The patients were then randomized to receive olanzapine or 
lithium monotherapy for 48 weeks. In this study, symptom-
atic recurrence of any mood episode following remission 
of mania or depression was 38.8% in lithium-treated group 
and 30.0% in the olanzapine-treated group. In evaluating 
pole-speciﬁ  c recurrences, there were no statistically signiﬁ  -
cant differences in the proportion of depressive recurrences 
(15.7% with olanzapine versus 10.7% with lithium; p = 0.15) 
though the trend favored lithium. However, a signiﬁ  cantly 
lower proportion of olanzapine-treated patients compared to 
the lithium-treated group had recurrence of manic (13.8% 
versus 23.4%; p = 0.02) or mixed episodes (0.5% versus 
4.7%; p = 0.005). Of note, the mean lithium level in the study 
is 0.76 mEq/L, which is within, but not near the upper end 
of, the therapeutic range. It is possible that a higher level 
would have been optimal for a number of the patients on 
lithium. Since the design required investigators to optimize 
lithium dose and reach a target blood level of 0.6–1.2 mEq/L 
by week 4 and most patients would be below the range ini-
tially, some investigators might have hesitated to increase 
the lithium dose once the target level was reached, resulting 
in a lower mean lithium level.
The most recent study evaluating efﬁ  cacy of olanzapine 
in the prevention of relapse of bipolar disorder affective epi-
sodes was a double-blind, placebo-controlled trial of a total 
of 361 patients (225 given olanzapine, 136 given placebo) 
for up to 48 weeks (Tohen et al 2006). This study enrolled 
patients who had achieved stabilization from a manic or 
mixed episode during 6–12 weeks of open-label therapy 
with olanzapine. Time to relapse was signiﬁ  cantly longer 
in the olanzapine-treated group than the placebo control 
(174 days versus 22 days; p   0.001). Also, the relapse 
rate was signiﬁ  cantly lower in the olanzapine-treated group 
(46.7% versus 80.1%) corresponding to a number needed to 
treat of 3.0 (95% CI 2.3–4.1), indicating that for every three Neuropsychiatric Disease and Treatment 2007:3(5) 584
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patients treated with olanzapine, a relapse would have been 
prevented for one patient during this time frame.
Based on the studies presented here, there seems to 
be sufﬁ  cient data to endorse the use of olanzapine in the 
maintenance of bipolar disorder, with evidence more clearly 
positive in prevention of mania and mixed states than in the 
prevention of depressive episodes.
Bipolar depression
Olanzapine-fluoxetine combination (OFC) therapy and 
quetiapine are the only FDA approved medications for the 
treatment of acute bipolar depression. There is some evidence 
to suggest that olanzapine monotherapy may have some ef-
ﬁ  cacy in depression, though it is clearly less effective than 
the combination therapy, based on current reported research 
studies. In a study by Tohen, Vieta et al (2003), the efﬁ  cacy 
of olanzapine and OFC therapy were compared to placebo 
in the treatment of bipolar I depression. The results of the 
study revealed that both olanzapine monotherapy and OFC 
were signiﬁ  cantly more effective than placebo from week 4 
to week 8 in decreasing symptoms of depression and pro-
ducing response and remission. The limitations of this study 
included a higher attrition rate and the lack of a ﬂ  uoxetine 
monotherapy comparison arm. However, this was the ﬁ  rst 
placebo-controlled trial comparing an antipsychotic or mood-
stabilizing agent alone and in combination with an antide-
pressant agent with the combination demonstrating a robust 
antidepressant effect with a lower risk of switching to mania. 
The study had lower rates of discontinuation due to adverse 
events with improved response and remission rates.
The 2002 American Psychiatric Association practice 
guidelines recommend lithium or lamotrigine as ﬁ  rst-line 
treatment for bipolar depression (APA 2006). In a 7-week ran-
domized, double-blind study comparing OFC to lamotrigine 
in the treatment of bipolar depression (Brown et al 2006), OFC 
demonstrated superior efﬁ  cacy to lamotrigine in improvement 
of depressive and manic symptoms in patients with bipolar 
I disorder. This study did not include a placebo arm and the 
dose of lamotrigine was escalated to 200 mg while previous 
studies in bipolar depression had demonstrated both 50 mg 
and 200 mg of lamotrigine to be effective. In this study treat-
ment differences in illness severity, depressive symptoms and 
manic symptoms favored OFC over lamotrigine that reached 
statistical signiﬁ  cance as early as week 1. Mean weight gain, 
dyslipidemias and prolactin elevations were observed in the 
OFC treated group compared to the lamotrigine treated group. 
A greater incidence in treatment emergent suicidal and self-
injurious behaviors was noticed in the lamotrigine treated 
group. This study lent further support for the use of OFC for 
treatment of bipolar depression.
Safety and tolerability issues
Individuals with severe persistent mental illness are at 
an increased risk for obesity, diabetes, hypertension, 
cardiovascular morbidity and mortality (McElroy et al 2002; 
Faglioni et al 2003; Basu et al 2004; Faglioni et al 2005). 
Patients with serious persistent mental disorders may be at 
an increased risk for metabolic issues because of a sedentary 
lifestyle and poor nutrition, lack of access to adequate medi-
cal care, nutrition and exercise programs. The prevalence 
rate of metabolic syndrome in bipolar disorder ranges from 
30%–42%, a proportion higher than the general population 
but similar to that observed in schizophrenia (30%–42%) 
(Basu et al 2004; Faglioni et al 2005; Goff et al 2005).
Treatment with a variety of psychotropic medications, 
including antipsychotics (Masand et al 2005; Newcomer 
2005), and mood stabilizers (Ness-Abramof and Apovian 
2005) may also result in weight gain. In bipolar disorder, 
sociodemographic factors associated with age, sex, income 
level, physical inactivity, comorbid binge eating, and 
treatment with some psychotropic medications have been 
identiﬁ  ed as clinical predictors of weight gain (Lipkovich 
et al 2006). Weight gain is a major contributor to medica-
tion non-adherence, subsequent relapse and poor prognosis 
(Brown et al 1999).
Review of evidence-based trials has demonstrated that 
clozapine and olanzapine are associated with a greater risk 
of clinically signiﬁ  cant weight gain with the other atypicals 
posing a relatively lower risk. The Consensus Panel guideline 
also provides some guidance based on evidence-based trials 
as to the propensity of second generation antipsychotics on 
weight gain, diabetes and dyslipidemias (ADA 2004). In a 
study by Lipkowich et al (2006), substantial amount of weight 
gain with olanzapine at the end of 30 weeks was predicted 
by weight increases of 2–3 kg within the ﬁ  rst 3 weeks of 
treatment. They also predicted that BMI close to normal 
( 27kg/m2) at treatment initiation also was a risk factor for 
future weight gain (Lipkovich et al 2006). Comparative trials 
have demonstrated mean body weight is signiﬁ  cantly greater 
in the olanzapine treated group versus lithium, valproic acid 
and other second generation antipsychotics (Tohen, Baker 
et al 2002; Zajecka et al 2002; Tohen, Goldberg et al 2003; 
Baker et al 2003[TC2]). Weight gain after longer exposure to 
olanzapine monotherapy was 2 kg compared to the combina-
tion of olanzapine with lithium or valproate demonstrating a 
weight increase of 5–6 kg (Bowden 2003).Neuropsychiatric Disease and Treatment 2007:3(5) 585
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Atypical antipsychotics have been associated with obe-
sity and other metabolic comorbidities. Published studies 
indicate that atypical antipsychotics alter glucose and lipid 
metabolism. Olanzapine with other atypical antipsychotics is 
at a substantially higher risk for impaired regulation, weight 
gain and dylipidemias. Hyperglycemia caused by olanzapine 
can progress to frank diabetes and diabetic ketoacidosis. Both 
acute phase and maintenance trials with olanzapine have 
demonstrated greater elevations in mean cholesterol and 
low density lipoprotein, albumin and total protein compared 
to valproic acid (Zajecka et al 2002; Tohen, Goldberg et al 
2003).
In short-term clinical trials 5–20 mg/day of olanzapine 
compared to placebo was associated with somnolence, 
dry mouth, dizziness, headaches, dyspepsia, agitation, 
asthenia, tremor and weight gain (Tohen et al 1999; 
Tohen et al 2000). There are at least two reported cases 
of olanzapine-induced pancreatitis (Doucette et al 2000; 
Waage et al 2004).
Laboratory abnormalities included a higher incidence 
of elevated liver enzyme values (ALT/SGPT) in the olan-
zapine group compared to the placebo group (17.6% versus 
0%) in one study (Tohen et al 1999). However, all of the 
ALT/SGPT values returned to normal during continued 
olanzapine treatment (Tohen et al 1999). A second study 
revealed a higher incidence of ALT and AST elevations in 
the olanzapine group compared to the placebo group (21.6% 
versus 3.9%) with only one (of 55 total) olanzapine-treated 
patient having the elevations at either end point or two 
consecutive observations (Tohen et al 2000). No patients in 
either study displayed clinical symptoms of hepatic dysfunc-
tion at any time during the study (Tohen et al 1999, 2000). 
In studies olanzapine has been shown to transiently elevate 
serum prolactin levels (Gorobets 2005). There have been no 
reports of clinically relevant ECG changes with olanzapine 
(Barak 2005).
Extrapyramidal symptoms were infrequent resulting in 
negligible use of anticholinergic agents in both short-term 
and long-term studies (Tohen et al 1999, 2000; Tohen, 
Baker et al 2002; Tohen, Chengappa et al 2002). Incidence 
of extrapyramidal symptoms (EPS) is similar between 
olanzapine and lithium, valproic acid but higher with halo-
peridol (Berk et al 1999; Tohen, Baker et al 2002; Zajecka 
et al 2002). It has been suggested that patients with affective 
disorders are at a higher risk of tardive dyskinesia. Second 
generation antipsychotics have demonstrated a lower risk of 
tardive dyskinesia compared to conventional antipsychotics. 
The risk of tardive dyskinesia with olanzapine in clinical 
trials was 1% compared to haloperidol 4.5% (Tollefson 
et al 1997).
Quality of life, patient satisfaction/
acceptability and adherence
The long-term treatment goal of remission and recovery 
that ultimately results in improved quality of life in Bipolar 
Disorder should focus on physical, emotional, occupational 
and social well being of the client. Few studies have evalu-
ated the impact of bipolar disorder on health related quality 
of life. In a review by Namjoshi et al (2001) bipolar patients 
seemed to report less satisfaction with their quality of life 
compared to patients with schizophrenia. This could also 
be as a result of higher level of education, ﬁ  nancial status 
and overall health status in patients’ with bipolar disorder 
compared to patients with schizophrenia (Atkinson et al 
1997). Women tend to report lower scores than men (Vojta 
et al 2001) while manic/hypomanic patients tend to report 
lower quality of life compared to euthymic patients. Depres-
sive symptoms also seem to play a role in the evaluation of 
quality of life (Namjoshi et al 2002).
Studies addressing quality-of-life outcomes with olanzap-
ine in patients with the diagnosis of bipolar I disorder manic or 
mixed episode included an acute phase followed by a 49-week 
open-label extension phase during which all patients were 
treated with olanzapine. The open-label extension allowed 
the use of lithium or ﬂ  uoxetine for patients with breakthrough 
episodes. Health-related quality of life assessment was 
measured using the Short Form-36 (SF-36) of the Medi-
cal Outcomes Study. Olanzapine-treated patients reported 
signiﬁ  cant improvements in manic symptoms as measured 
by YMRS scores during the 3-week acute phase compared 
with the placebo-treated group. A signiﬁ  cant improvement in 
the olanzapine-treated patients on the “physical functioning” 
dimension of SF-36 compared with placebo was evidence. 
In the 49 week open label extension phase more olanzapine-
treated than placebo-treated patients were discharged from the 
hospital and further improvements on all SF-36 dimensions 
compared with at the end of the acute treatment period was 
observed. A correlation between improvements on the YMRS 
and SF-36, suggested olanzapine treated patients may start 
to experience functional improvement as well (Namjoshi et 
al 2002). In other studies olanzapine as an add on to lithium 
or valproic acid demonstrated combination treatment dem-
onstrated an improvement on the YMRS, HAM-D as well 
as the Lehrman’s quality of life scale; thereby suggesting 
the beneﬁ  ts of olanzapine in symptom improvement, social 
functioning and the overall quality of life (Shi 2002).Neuropsychiatric Disease and Treatment 2007:3(5) 586
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Patients with a negative attitude toward treatment either 
due to illness, efﬁ  cacy or adverse events, are also more likely 
to be non-adherent. Non-adherence is a common occurrence 
in patients with bipolar disorder and is often closely linked 
to relapse and rehospitalization. Comorbid substance abuse, 
little family involvement, and a poor clinician-patient rela-
tionship are among the other risk factors for non-adherence 
(Revicki 2005).
Strategies for improving adherence
Strategies to improve adherence include optimizing anti-
psychotic therapy, minimizing adverse events, encouraging 
patient participation in psychoeducational programs, treating 
comorbid substance abuse disorders, involving family mem-
bers in the treatment process, and forging a close therapeutic 
relationship with the patient.
Selecting an effective antipsychotic that the patient can 
tolerate is the ﬁ  rst step in improving adherence (Krebs et al 
2006). Because EPS, weight gain, and sexual dysfunction 
appear to have the greatest negative impact on adherence, 
antipsychotics least likely to cause these adverse events 
should be the ﬁ  rst choice for initial treatment. Atypical 
antipsychotics like olanzapine may be of particular beneﬁ  t in 
conjunction with psychoeducational programs because these 
agents, apart from their efﬁ  cacy for mood stabilizing effects, 
positive, negative symptoms, may also improve cognition 
(Milklowitz 2006).
Improving adherence involves collaboration between 
the clinician, patient, and family members. Interventions to 
improve adherence includes optimizing pharmacotherapeutic 
treatments by incorporating psychosocial strategies. Psycho-
educational programs with behavioral interventions based 
on motivational interviewing, problem solving, supportive 
services, family education, assertive community training are 
likely to improve adherence (Milklowitz 2006).
Conclusion
Most published studies on olanzapine have dealt with is-
sues related to efﬁ  cacy and safety, with a handful devoted 
to quality of life measures. More recent independently 
funded studies including the Clinical Antipsychotic Trial 
of Interventions Effectiveness (CATIE), Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D) and 
Systematic Treatment Enhancement Program in Bipolar 
Disorder (STEP-BD) have focused on effectiveness in 
terms of important outcomes such as medication-adherence 
behavior, quality of life, subjective tolerability, and overall 
satisfaction with treatment. (Goff et al 2005; Rush et al 
2006; Nierenberg et al 2006). There is an urgent need for 
well-designed, controlled, and adequately powered stud-
ies before any ﬁ  rm conclusions can be reached. A strong 
therapeutic alliance, combined with psychoeducation and 
adequate monitoring of symptoms and adverse effects 
should serve as a premise for treatment adherence. Multi-
modal treatment approaches including lifestyle modiﬁ  ca-
tion including diet and exercise when feasible are more 
likely to foster adherence since they address a wider array 
of problem areas. Improving patient adherence to anti-
psychotic maintenance therapy is crucial to any effort to 
decrease rates of relapse and rehospitalization in patients 
with schizophrenia. However, the adverse event proﬁ  le 
must be taken into account in reaching a prescribing deci-
sion based on weighing the advantages and disadvantages 
for the individual bipolar patient.
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